Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
69 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03918278 | A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) | completed | Phase 1 | 222 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Jun 25, 2025 | clinicaltrials |
| NCT05625412 | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | completed | Phase 1 | 70 | Bristol-Myers SquibbINDUSTRY | 9 | Jun 13, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT04418661 | Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies | terminated | Phase 1 / Phase 2 | 65 | SanofiINDUSTRY | 7 | May 29, 2025 | clinicaltrials |
| NCT03110107 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 376 | Bristol-Myers SquibbINDUSTRY | 17 | Apr 24, 2025 | clinicaltrials |
| NCT02913313 | A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 101 | Bristol-Myers SquibbINDUSTRY | 8 | Apr 20, 2025 | clinicaltrials |
| NCT04943900 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | completed | Phase 1 | 67 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 9, 2025 | clinicaltrials |
| NCT03179436 | Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | completed | Phase 1 / Phase 2 | 415 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT02635672 | Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | completed | Phase 1 | 110 | Vincerx Pharma, Inc.INDUSTRY | 3 | Nov 15, 2024 | clinicaltrials |
| NCT01084252 | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 351 | SanofiINDUSTRY | 17 | Nov 1, 2024 | clinicaltrials |
| NCT06556004 | Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients(Trimelvax001) | unknown | Phase 1 | 20 | University of ChileOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT03980314 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | completed | Phase 1 | 261 | Bristol-Myers SquibbINDUSTRY | 14 | Dec 15, 2023 | clinicaltrials |
| NCT06152367 | Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients | completed | Phase 1 / Phase 2 | 90 | University of ChileOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03985072 | Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor | completed | Phase 1 | 67 | Andes BiotechnologiesINDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT01512199 | Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) | terminated | Phase 1 / Phase 2 | 29 | Daiichi SankyoINDUSTRY | 2 | Oct 18, 2017 | clinicaltrials |
| NCT00560235 | Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors | completed | Phase 1 / Phase 2 | 138 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00630110 | Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 172 | Nereus Pharmaceuticals, Inc.INDUSTRY | 6 | Aug 16, 2011 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials